Efficacy of tofacitinib as an induction agent in severe alopecia areata compared to oral betamethasone weekly pulse

A few studies have looked at the efficacy of tofacitinib in severe alopecia areata (AA), characterized by ≥ 50% scalp hair loss. Here, we aimed to assess retrospective data for the role of tofacitinib as an induction agent in severe AA, compared with the standard oral mini-pulse (OMP). Tofacitinib holds promise as an induction agent for patients with severe AA, comparable with OMP. However, when patients respond inadequately to tofacitinib, a trial of pulse steroids may be considered.